A reduced incidence and regression of Kaposi's sarcoma (KS) and other tumours has been reported in Acquired Immune Deficiency Syndrome (AIDS) patients treated with antiretroviral combination therapies containing Human Immunodeficiency Virus (HIV) protease inhibitors (PIs) such as indinavir or saquinavir. Indeed, evidence indicates that although PIs were designed to selectively inhibit the HIV protease activity, they can interfere with several cellular pathways and can inhibit tumour growth. In particular, our recent results indicate that doses of indinavir or saquinavir similar to those employed to treat AIDS patients can induce regression of experimental KS by directly blocking two fundamental steps of KS initiation and progression: new blood vessel formation (angiogenesis) and KS tumour cell invasion. This is because indinavir or saquinavir inhibit the activation of matrix metalloproteinase-2 (MMP-2), a basement membrane-degrading enzyme, which is required for the progression of most tumours. Based on these results, a multicentre clinical trial is now starting in Italy, which will assess PI effects on the progression of KS in HIV-uninfected individuals (classical KS).

Barillari, G., Sgadari, C., Toschi, E., Monini, P., & Ensoli, B. (2003). HIV protease inhibitors as new treatment options for Kaposi's sarcoma. DRUG RESISTANCE UPDATES, 6(4), 173-181 [10.1016/S1368-7646(03)00060-8].

HIV protease inhibitors as new treatment options for Kaposi's sarcoma

BARILLARI, GIOVANNI;
2003-08

Abstract

A reduced incidence and regression of Kaposi's sarcoma (KS) and other tumours has been reported in Acquired Immune Deficiency Syndrome (AIDS) patients treated with antiretroviral combination therapies containing Human Immunodeficiency Virus (HIV) protease inhibitors (PIs) such as indinavir or saquinavir. Indeed, evidence indicates that although PIs were designed to selectively inhibit the HIV protease activity, they can interfere with several cellular pathways and can inhibit tumour growth. In particular, our recent results indicate that doses of indinavir or saquinavir similar to those employed to treat AIDS patients can induce regression of experimental KS by directly blocking two fundamental steps of KS initiation and progression: new blood vessel formation (angiogenesis) and KS tumour cell invasion. This is because indinavir or saquinavir inhibit the activation of matrix metalloproteinase-2 (MMP-2), a basement membrane-degrading enzyme, which is required for the progression of most tumours. Based on these results, a multicentre clinical trial is now starting in Italy, which will assess PI effects on the progression of KS in HIV-uninfected individuals (classical KS).
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/05 - Patologia Clinica
English
Con Impact Factor ISI
Animals; Antiretroviral Therapy, Highly Active; HIV Protease Inhibitors; Humans; Italy; Sarcoma, Kaposi
Barillari, G., Sgadari, C., Toschi, E., Monini, P., & Ensoli, B. (2003). HIV protease inhibitors as new treatment options for Kaposi's sarcoma. DRUG RESISTANCE UPDATES, 6(4), 173-181 [10.1016/S1368-7646(03)00060-8].
Barillari, G; Sgadari, C; Toschi, E; Monini, P; Ensoli, B
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/188398
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact